Summary of findings 5. Fluoxetine compared to amisulpride.
| Fluoxetine compared to amisulpride | ||||||
| Patient or population: patients with depression Settings: in‐ and outpatients Intervention: fluoxetine Comparison: amisulpride | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Amisulpride | Fluoxetine | |||||
|
Failure to respond (reduction ≥ 50% on HDRS) |
0 per 1000 (0 to 0) | Not estimable | 0 (0) | |||
|
Endpoint score (HDRS or MADRS) |
The mean endpoint score in the intervention groups was 0.17 standard deviations higher (0.07 lower to 0.41 higher) | 268 (1 study) | ⊕⊕⊝⊝ low1 | This corresponds to a very small effect according to conventions proposed by Cohen 1992 | ||
| Failure to complete ‐ total ‐ | 225 per 1000 | 288 per 1000 (191 to 409) | OR 1.39 (0.81 to 2.38) | 281 (1 study) | ⊕⊕⊝⊝ low1 | |
| Failure to complete ‐ inefficacy ‐ | 56 per 1000 | 65 per 1000 (25 to 156) | OR 1.16 (0.43 to 3.10) | 281 (1 study) | ⊕⊕⊝⊝ low1 | |
| Failure to complete ‐ side effects ‐ | 92 per 1000 | 72 per 1000 (32 to 155) | OR 0.77 (0.33 to 1.82) | 281 (1 study) | ⊕⊕⊝⊝ low1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested. Only one study included in the analysis.